Evidence map›Paper›PMID 24881821›Full record

ArticleAmerican journal of obstetrics and gynecology2014

Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention--convened meeting.

Cheryl S Broussard, Meghan T Frey, Sonia Hernandez-Diaz, Michael F Greene, Christina D Chambers, Leyla Sahin, Beth A Collins Sharp, Margaret A Honein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of obstetrics and gynecology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Clinical management of medications in pregnancy and lactation.American journal of obstetrics and gynecology · 2016
    Article
  11. Article
  12. Reply: To PMID 24881821.American journal of obstetrics and gynecology · 2015
    Article
  13. Article
  14. Designing drug trials: considerations for pregnant women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Cheryl S BroussardNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA. Electronic address: cbroussard@cdc.gov.
Meghan T FreyNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Oak Ridge Institute for Science and Education, Oak Ridge, TN.
Sonia Hernandez-DiazHarvard School of Public Health, Boston, MA.
Michael F GreeneDepartment of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School and Massachusetts General Hospital, Boston, MA.
Christina D ChambersDepartments of Pediatrics and Family and Preventive Medicine, University of California, San Diego, La Jolla, CA.
Leyla SahinPediatric and Maternal Health Staff, Maternal Health Team, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
Beth A Collins SharpAgency for Healthcare Research and Quality, Rockville, MD.
Margaret A HoneinNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

To address information gaps that limit informed clinical decisions on medication use in pregnancy, the Centers for Disease Control and Prevention (CDC) solicited expert input on a draft prototype outlining a systematic approach to evaluating the quality and strength of existing evidence for associated risks. The draft prototype outlined a process for the systematic review of available evidence and deliberations by a panel of experts to inform clinical decision making for managing health conditions in pregnancy. At an expert meeting convened by the CDC in January 2013, participants divided into working groups discussed decision points within the prototype. This report summarizes their discussions of best practices for formulating an expert review process, developing evidence summaries and treatment guidance, and disseminating information. There is clear recognition of current knowledge gaps and a strong collaboration of federal partners, academic experts, and professional organizations willing to work together toward safer medication use during pregnancy.

Indexed as

Abnormalities, Drug-InducedAnimalsCenters for Disease Control and Prevention, U.S.FemaleFetusHumansPractice Guidelines as TopicPregnancyPregnancy ComplicationsSafetyUnited StatesCenters for Disease Control and Preventionexpert reviewmedicationspregnancyteratogens

Identifiers

PMID24881821
PMCPMC4484789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.